The U.S. Food and Drug Administration has approved Jazz Pharmaceuticals' new treatment for a rare brain tumor, offering a novel therapeutic option for patients with limited alternatives. This regulatory greenlight marks a significant advancement in addressing unmet medical needs within neuro-oncology. Jazz Pharma's development highlights the ongoing push to provide targeted therapies for rare and difficult-to-treat cancers.